The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Response and Resistance to BCR-ABL1-Targeted Therapies
Open accessAbstract
Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine kinase, has served as a paradigm for successful application of molecularly targeted cancer therapy. The development of the tyrosine kinase inhibitor (TKI) imatinib allows patients with CML to experience near-normal life expectancy. Specific point mutations that decrease drug binding affinity can produce TKI resistance, and second-and third-generation TKIs largely mitigate this problem. Some patients develop TKI resistance without known resistance mutations, with significant heterogeneity in the underlying mechanism, but this is relatively uncommon, with the majority of patients with chronic phase CML achieving long-term disease control. In contrast, responses to TKI treatment are short lived in advanced phases of the disease or in BCR-ABL1-positive acute lymphoblastic leukemia, with relapse driven by both BCR-ABL1 kinase-dependent and -independent mechanisms. Additionally, the frontline CML treatment with second-generation TKIs produces deeper molecular responses, driving disease burden below the detection limit for a greater number of patients. For patients with deep molecular responses, up to half have been able to discontinue therapy. Current efforts are focused on identifying therapeutic strategies to drive deeper molecular responses, enabling more patients to attempt TKI discontinuation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Iqbal, Z., Aleem, A., Iqbal, M., Naqvi, M. I., Gill, A. T., Taj, A. S., Qayyum, A., ur-Rehman, N., Khalid, A. M., Shah, I. H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055717 · Cited by 44
RetractedRevised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationA minute chromosome in human chronic granulocytic leukemia
Nowell̀, P. C. (1960) · Science · Cited by 2,269
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Self-citationOverriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
GROFFEN, J., STEPHENSON, J., HEISTERKAMP, N., DEKLEIN, A., BARTRAM, C., & GROSVELD, G. (1984) · Cell · doi:10.1016/0092-8674(84)90077-1 · Cited by 1,599
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Mahon, F.-X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70233-3 · Cited by 1,550
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,344
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., Baccarani, M., Deininger, M. W., Cervantes, F., Fujihara, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609324 · Cited by 1,285
Self-citationTyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281
O'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,259
Self-citationHughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218
Hughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,199
Sawyers, C. L. (2002) · Blood · doi:10.1182/blood.v99.10.3530 · Cited by 1,146
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Cortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boqué, C., Shah, N. P., Chuah, C., Casanova, L., Bradley-Garelik, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8899 · Cited by 947
Nagar, B., Bornmann, W. G., Pellicena, P., Schindler, T. H., Veach, D. R., Miller, W. T., Clarkson, B. D., & Kuriyan, J. (2002) · PubMed · Cited by 923
Marin, D., Bazeos, A., Mahon, F.-X., Eliasson, L., Milojkovic, D., Bua, M., Apperley, J. F., Szydlo, R., Desai, R., Kozlowski, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3087 · Cited by 909
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
Zhao, C., Chen, A., Jamieson, C. H., Fereshteh, M., Abrahamsson, A., Blum, J., Kwon, H. Y., Kim, J., Chute, J. P., Rizzieri, D., et al. (2009) · Nature · doi:10.1038/nature07737 · Cited by 869
Hochhaus, A., Saglio, G., Hughes, T. P., Larson, R. A., Kim, D.-W., Issaragrisil, S., le Coutre, P. D., Etienne, G., Dorlhiac-Llacer, P. E., Clark, R. E., et al. (2016) · Leukemia · doi:10.1038/leu.2016.5 · Cited by 839
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Blanke, C. D., Demetri, G. D., Joensuu, H., Roberts, P. J., Eisenberg, B. L., von Mehren, M., Fletcher, C. D. M., Sandau, K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2265 · Cited by 814
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205127 · Cited by 769
Self-citationCorbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
Self-citationThe great escape: tumour cell plasticity in resistance to targeted therapy
Boumahdi, S., & de Sauvage, F. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 761
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Smith, C. C., Wang, Q., Chin, C.-S., Salerno, S., Damon, L. E., Levis, M. J., Perl, A. E., Travers, K. J., Wang, S., Hunt, J. P., et al. (2012) · Nature · doi:10.1038/nature11016 · Cited by 735
Ross, D. M., Branford, S., Seymour, J. F., Schwarer, A. P., Arthur, C., Yeung, D. T., Dang, P., Goyne, J. M., Slader, C., Filshie, R. J., et al. (2013) · Blood · doi:10.1182/blood-2013-02-483750 · Cited by 710
Tokarski, J. S., Newitt, J. A., Chang, C. Y. J., Cheng, J. D., Wittekind, M., Kiefer, S. E., Kish, K., Lee, F. Y. F., Borzillerri, R., Lombardo, L. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4187 · Cited by 700
Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., & Talpaz, M. (2003) · Blood · doi:10.1182/blood.v101.2.690 · Cited by 663
Pendergast, A. M., Quilliam, L. A., Cripe, L. D., Bassing, C. H., Dai, Z., Li, N., Batzer, A., Rabun, K. M., Der, C. J., Schlessinger, J., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90689-n · Cited by 659
Saussele, S., Richter, J., Guilhot, J., Gruber, F. X., Hjorth-Hansen, H., Almeida, A., Janssen, J. J. W. M., Mayer, J., Koskenvesa, P., Panayiotidis, P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30192-x · Cited by 618
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Wylie, A. A., Schoepfer, J., Jahnke, W., Cowan-Jacob, S. W., Loo, A., Furet, P., Marzinzik, A. L., Pelle, X., Donovan, J., Zhu, W., et al. (2017) · Nature · doi:10.1038/nature21702 · Cited by 614
Bellodi, C., Lidonnici, M. R., Hamilton, A., Helgason, G. V., Soliera, A. R., Ronchetti, M., Galavotti, S., Young, K. W., Selmi, T., Yacobi, R., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci35660 · Cited by 570
Ottmann, O. G. (2002) · Blood · doi:10.1182/blood-2001-12-0181 · Cited by 555
Rousselot, P., Huguet, F., Rea, D., Legros, L., Cayuela, J. M., Maarek, O., Blanchet, O., Marit, G., Gluckman, E., Reiffers, J., et al. (2007) · Blood · doi:10.1182/blood-2006-03-011239 · Cited by 538
PML targeting eradicates quiescent leukaemia-initiating cells
Ito, K., Bernardi, R., Morotti, A., Matsuoka, S., Saglio, G., Ikeda, Y., Rosenblatt, J., Avigan, D. E., Teruya-Feldstein, J., & Pandolfi, P. P. (2008) · Nature · doi:10.1038/nature07016 · Cited by 538
Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation
Dierks, C., Beigi, R., Guo, G.-R., Zirlik, K., Stegert, M. R., Manley, P., Trussell, C., Schmitt-Graeff, A., Landwerlin, K., Veelken, H., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.003 · Cited by 517
Cortes, J. E., Gambacorti-Passerini, C., Deininger, M. W., Mauro, M. J., Chuah, C., Kim, D.-W., Dyagil, I., Glushko, N., Milojkovic, D., le Coutre, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7162 · Cited by 495
Shah, N. P., Kantarjian, H. M., Kim, D.-W., Réa, D., Dorlhiac-Llacer, P. E., Milone, J. H., Vela-Ojeda, J., Silver, R. T., Khoury, H. J., Charbonnier, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9260 · Cited by 489
A Myristoyl/Phosphotyrosine Switch Regulates c-Abl
Hantschel, O., Nagar, B., Guettler, S., Kretzschmar, J., Dorey, K., Kuriyan, J., & Superti-Furga, G. (2003) · Cell · doi:10.1016/s0092-8674(03)00191-0 · Cited by 480
Peng, B., Hayes, M., Resta, D., Racine-Poon, A., Druker, B. J., Talpaz, M., Sawyers, C. L., Rosamilia, M., Ford, J., Lloyd, P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.050 · Cited by 472
Self-citationAsciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., DeAngelo, D. J., Breccia, M., Goh, Y.-T., Talpaz, M., Hochhaus, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902328 · Cited by 471
Self-citationChronic Myelogenous Leukemia: Biology and Therapy
Faderl, S., Talpaz, M., Estrov, Z., & Kantarjian, H. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-3-199908030-00008 · Cited by 462
Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia
Johansson, B., Fioretos, T., & Mitelman, F. (2002) · Acta Haematologica · doi:10.1159/000046636 · Cited by 454
Schultz, K. R., Carroll, A., Heerema, N. A., Bowman, W. P., Aledo, A., Slayton, W. B., Sather, H., Devidas, M., Zheng, H. W., Davies, S. M., et al. (2014) · Leukemia · doi:10.1038/leu.2014.30 · Cited by 447
Shah, N. P., Skaggs, B. J., Branford, S., Hughes, T. P., Nicoll, J. M., Paquette, R. L., & Sawyers, C. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30890 · Cited by 418
Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1
Awad, M. M., Katayama, R., McTigue, M., Liu, W., Deng, Y.-L., Brooun, A., Friboulet, L., Huang, D., Falk, M. D., Timofeevski, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215530 · Cited by 416
Li, L., Wang, L., Li, L., Wang, Z., Ho, Y., McDonald, T., Holyoake, T. L., Chen, W., & Bhatia, R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.020 · Cited by 410
Golas, J. M., Arndt, K. T., Etienne, C., Lucas, J., Nardin, D., Gibbons, J. J., Frost, P., Ye, F., Boschelli, D. H., & Boschelli, F. (2003) · PubMed · Cited by 408
Giustacchini, A., Thongjuea, S., Barkas, N., Woll, P. S., Povinelli, B. J., Booth, C. A. G., Sopp, P., Norfo, R., Rodriguez-Meira, A., Ashley, N., et al. (2017) · Nature Medicine · doi:10.1038/nm.4336 · Cited by 403 · cited 1×
“Single-cell RNA sequencing of CML stem cells revealed a quiescent population with transcriptional evidence of both JAK/STAT and TNF pathway activation as compared with normal stem cells (Giustacchini et al., 2017).”
BackgroundPractical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib
Deininger, M. W. N., O’Brien, S. G., Ford, J. M., & Druker, B. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.143 · Cited by 402
Self-citationActivity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
Redaelli, S., Piazza, R., Rostagno, R., Magistroni, V., Perini, P., Marega, M., Gambacorti-Passerini, C., & Boschelli, F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8853 · Cited by 399
Pane, F., Frigeri, F., Sindona, M., Luciano, L., Ferrara, F., Cimino, R., Meloni, G., Saglio, G. N., Salvatore, F., & Rotoli, B. (1996) · Blood · doi:10.1182/blood.v88.7.2410.bloodjournal8872410 · Cited by 387
In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor
le Coutre, P., Mologni, L., Cleris, L., Marchesi, E., Buchdunger, E., Giardini, R., Formelli, F., & Gambacorti-Passerini, C. (1999) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/91.2.163 · Cited by 374
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
Rossari, F., Minutolo, F., & Orciuolo, E. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0624-2 · Cited by 371
Critical role for Gab2 in transformation by BCR/ABL
Sattler, M., Mohi, M. G., Pride, Y. B., Quinnan, L. R., Malouf, N. A., Podar, K., Gesbert, F., Iwasaki, H., Li, S., Van Etten, R. A., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00074-0 · Cited by 364
Zabriskie, M. S., Eide, C. A., Tantravahi, S. K., Vellore, N. A., Estrada, J., Nicolini, F. E., Khoury, H. J., Larson, R. A., Konopleva, M., Cortes, J. E., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.006 · Cited by 363
Self-citationfor the SAKK and the German CML Study Group, Hehlmann, R., Lauseker, M., Saußele, S., Pfirrmann, M., Krause, S., Kolb, H. J., Neubauer, A., Hossfeld, D. K., Nerl, C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.253 · Cited by 341
Marin, D., Milojkovic, D., Olavarria, E., Khorashad, J. S., de Lavallade, H., Reid, A. G., Foroni, L., Rezvani, K., Bua, M., Dazzi, F., et al. (2008) · Blood · doi:10.1182/blood-2008-06-162388 · Cited by 328
Rea, D., Nicolini, F. E., Tulliez, M., Guilhot, F., Guilhot, J., Guerci-Bresler, A., Gardembas, M., Coiteux, V., Guillerm, G., Legros, L., et al. (2017) · Blood · doi:10.1182/blood-2016-09-742205 · Cited by 317
Ibrahim, A. R., Eliasson, L., Apperley, J. F., Milojkovic, D., Bua, M., Szydlo, R., Mahon, F.-X., Kozlowski, K., Paliompeis, C., Foroni, L., et al. (2011) · Blood · doi:10.1182/blood-2010-10-309807 · Cited by 316
Burgess, M. R., Skaggs, B. J., Shah, N. P., Lee, F. Y., & Sawyers, C. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409770102 · Cited by 313
Imagawa, J., Tanaka, H., Okada, M., Nakamae, H., Hino, M., Murai, K., Ishida, Y., Kumagai, T., Sato, S., Ohashi, K., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00196-9 · Cited by 306
BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance
Koptyra, M., Falinski, R., Nowicki, M. O., Stoklosa, T., Majsterek, I., Nieborowska-Skorska, M., Blasiak, J., & Skorski, T. (2006) · Blood · doi:10.1182/blood-2005-07-2815 · Cited by 298
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
Cowan-Jacob, S. W., Fendrich, G., Floersheimer, A., Furet, P., Liebetanz, J., Rummel, G., Rheinberger, P., Centeleghe, M., Fabbro, D., & Manley, P. W. (2007) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906047287 · Cited by 296
Hochhaus, A., Masszi, T., Giles, F. J., Radich, J. P., Ross, D. M., Gómez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., García-Gutiérrez, V, et al. (2017) · Leukemia · doi:10.1038/leu.2017.63 · Cited by 293
Hehlmann, R. (2012) · Blood · doi:10.1182/blood-2012-03-380147 · Cited by 273
Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Assouline, S., Etienne, G., Nicolini, F. E., le Coutre, P., Clark, R. E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00080-2 · Cited by 265
A population-based cytogenetic study of adults with acute lymphoblastic leukemia
Moorman, A. V., Chilton, L., Wilkinson, J., Ensor, H. M., Bown, N., & Proctor, S. J. (2010) · Blood · doi:10.1182/blood-2009-07-232124 · Cited by 247
Eide, C. A., Zabriskie, M. S., Savage Stevens, S. L., Antelope, O., Vellore, N. A., Than, H., Schultz, A. R., Clair, P., Bowler, A. D., Pomicter, A. D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.004 · Cited by 247
Self-citationShah, N. P., Kasap, C., Weier, C., Balbas, M., Nicoll, J. M., Bleickardt, E., Nicaise, C., & Sawyers, C. L. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.11.001 · Cited by 230
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
Burchert, A., Wang, Y., Cai, D., von Bubnoff, N., Paschka, P., Müller-Brüsselbach, S., Ottmann, O. G., Duyster, J., Hochhaus, A., & Neubauer, A. (2005) · Leukemia · doi:10.1038/sj.leu.2403898 · Cited by 213
Branford, S., Wang, P., Yeung, D. T., Thomson, D., Purins, A., Wadham, C., Shahrin, N. H., Marum, J. E., Nataren, N., Parker, W. T., et al. (2018) · Blood · doi:10.1182/blood-2018-02-832253 · Cited by 210
Chissoe, S. L., Bodenteich, A., Wang, Y.-F., Wang, Y.-P., Burian, D., Clifton, S. W., Crabtree, J., Freeman, A., Iyer, K., Jian, L., et al. (1995) · Genomics · doi:10.1006/geno.1995.1008 · Cited by 206
DNA Contents of Chromosome Ph 1 and Chromosome 21 in Human Chronic Granulocytic Leukemia
Rudkin, G. T., Hungerford, D. A., & Nowell, P. C. (1964) · Science · doi:10.1126/science.144.3623.1229 · Cited by 198
Warsch, W., Kollmann, K., Eckelhart, E., Fajmann, S., Cerny-Reiterer, S., Hölbl, A., Gleixner, K. V., Dworzak, M., Mayerhofer, M., Hoermann, G., et al. (2011) · Blood · doi:10.1182/blood-2009-10-248211 · Cited by 194
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia
Hantschel, O., Warsch, W., Eckelhart, E., Kaupe, I., Grebien, F., Wagner, K.-U., Superti-Furga, G., & Sexl, V. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.775 · Cited by 183
Grossmann, V, Kohlmann, A., Zenger, M., Schindela, S., Eder, C., Weissmann, S., Schnittger, S., Kern, W., Müller, M. C., Hochhaus, A., et al. (2011) · Leukemia · doi:10.1038/leu.2010.298 · Cited by 180
Wnt/Ca2+/NFAT Signaling Maintains Survival of Ph+ Leukemia Cells upon Inhibition of Bcr-Abl
Gregory, M. A., Phang, T. L., Neviani, P., Alvarez-Calderon, F., Eide, C. A., O'Hare, T., Zaberezhnyy, V., Williams, R. T., Druker, B. J., Perrotti, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.025 · Cited by 180
Self-citationCharting the molecular network of the drug target Bcr-Abl
Brehme, M., Hantschel, O., Colinge, J., Kaupe, I., Planyavsky, M., Köcher, T., Mechtler, K., Bennett, K. L., & Superti-Furga, G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900653106 · Cited by 170
Gallipoli, P., Cook, A., Rhodes, S., Hopcroft, L., Wheadon, H., Whetton, A. D., Jørgensen, H. G., Bhatia, R., & Holyoake, T. L. (2014) · Blood · doi:10.1182/blood-2013-12-545640 · Cited by 158
Janus Kinase 2: A Critical Target in Chronic Myelogenous Leukemia
Samanta, A. K., Lin, H., Sun, T., Kantarjian, H. M., & Arlinghaus, R. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0025 · Cited by 157
Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition
Scott, M. T., Korfi, K., Saffrey, P., Hopcroft, L. E. M., Kinstrie, R., Pellicano, F., Guenther, C., Gallipoli, P., Cruz, M. M. A., Dunn, K. M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0263 · Cited by 153
Efficace, F., Baccarani, M., Breccia, M., Cottone, F., Alimena, G., Deliliers, G. L., Baratè, C., Specchia, G., Lorenzo, R. D., Luciano, L., et al. (2013) · Leukemia · doi:10.1038/leu.2013.51 · Cited by 152
Porkka, K., Khoury, H. J., PAQUETTE, R. L., Matloub, Y., Sinha, R., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24734 · Cited by 152
Levinson, N. M., & Boxer, S. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029828 · Cited by 149
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia
on behalf of the International CML Foundation Genomics Alliance, Branford, S., Kim, D. D. H., Apperley, J. F., Eide, C. A., Mustjoki, S., Ong, S. T., Nteliopoulos, G., Ernst, T., Chuah, C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0512-y · Cited by 149
Self-citationWang, Y., Cai, D., Brendel, C. A., Barett, C., Erben, P., Manley, P. W., Hochhaus, A., Neubauer, A., & Burchert, A. (2006) · Blood · doi:10.1182/blood-2006-08-040022 · Cited by 147
Involvement of Jak2 tyrosine phosphorylation in Bcr–Abl transformation
Xie, S., Wang, Y., Liu, J., Sun, T., Wilson, M. B., Smithgall, T. E., & Arlinghaus, R. B. (2001) · Oncogene · doi:10.1038/sj.onc.1204834 · Cited by 146
Senechal, K., Halpern, J., & Sawyers, C. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.38.23255 · Cited by 141
Schmidt, T., Masouleh, B. K., Loges, S., Cauwenberghs, S., Fraisl, P., Maes, C., Jonckx, B., Keersmaecker, K. D., Kleppe, M., Tjwa, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.007 · Cited by 140
Mahon, F., Boquimpani, C. M., Kim, D., Benyamini, N., Clementino, N. C. D., Shuvaev, V. A., Ailawadhi, S., Lipton, J. H., Turkina, A., de Paz, R., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m17-1094 · Cited by 138
Jones, D. M., Thomas, D. M., Yin, C. C., O'Brien, S. M., Cortes, J. E., Jabbour, E. J., Breeden, M., Giles, F. J., Zhao, W., & Kantarjian, H. M. (2008) · Cancer · doi:10.1002/cncr.23666 · Cited by 137
Million, R. P., & Etten, R. A. V. (2000) · Blood · doi:10.1182/blood.v96.2.664 · Cited by 136
Hazarika, M., Jiang, X., Liu, Q., Lee, S., Ramchandani, R. P., Garnett, C. E., Orr, M. S., Sridhara, R., Booth, B. P., Leighton, J. K., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0308 · Cited by 136
Eisterer, W., Jiang, X., Christ, O., Glimm, H., Lee, K. H., Pang, E., Lambie, K., Shaw, G., Holyoake, T. L., Petzer, A. L., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403649 · Cited by 135
Blast crisis of chronic granulocytic leukemia
Rosenthal, S. N., Canellos, G. P., Whang‐Peng, J., & Gralnick, H. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90199-1 · Cited by 126
Packer, L., Rana, S., Hayward, R., O’Hare, T., Eide, C. A., Rebocho, A. P., Heidorn, S. J., Zabriskie, M. S., Niculescu‐Duvaz, I., Druker, B. J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.004 · Cited by 125
Self-citationHe, Y., Wertheim, J. A., Xu, L., Miller, J. P., Karnell, F. G., Choi, J. K., Ren, R., & Pear, W. S. (2002) · Blood · doi:10.1182/blood.v99.8.2957 · Cited by 121
Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia
Legros, L., Nicolini, F. E., Étienne, G., Rousselot, P. H., Réa, D., Giraudier, S., Guerci‐Bresler, A., Huguet, F., Gardembas, M., Escoffre‐Barbe, M., et al. (2017) · Cancer · doi:10.1002/cncr.30885 · Cited by 115
Horowitz, M. M., Rowlings, P., & Passweg, J. R. (1996) · PubMed · Cited by 114
Wang, J., Shen, Z., Saglio, G. N., Jin, J., Huang, H., Hu, Y., Du, X., Li, J., Meng, F., Zhu, H., et al. (2015) · Blood · doi:10.1182/blood-2014-09-601674 · Cited by 113
Deininger, M. W., Hodgson, J., Shah, N. P., Cortes, J. E., Kim, D., Nicolini, F. E., Talpaz, M., Baccarani, M., Müller, M. C., Li, J., et al. (2015) · Blood · doi:10.1182/blood-2015-08-660977 · Cited by 110
Bocchia, M., Sicuranza, A., Abruzzese, E., Iurlo, A., Sirianni, S., Gozzini, A., Galimberti, S., Aprile, L., Martino, B., Pregno, P., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00194 · Cited by 110
Reckel, S., Hamelin, R., Georgeon, S., Armand, F., Jolliet, Q., Chiappe, D., Moniatte, M., & Hantschel, O. D. (2017) · Leukemia · doi:10.1038/leu.2017.36 · Cited by 107
Traer, E. A., MacKenzie, R. J., Snead, J. L., Agarwal, A., Eiring, A. M., O’Hare, T., Druker, B. J., & Deininger, M. W. (2011) · Leukemia · doi:10.1038/leu.2011.325 · Cited by 106
Self-citationGioia, R., Leroy, C., Drullion, C., Lagarde, V., Étienne, G., Dulucq, S., Lippert, É., Roche, S., Mahon, F., & Pasquet, J. (2011) · Blood · doi:10.1182/blood-2010-10-313692 · Cited by 101
Soverini, S., Bavaro, L., De Benedittis, C., Martelli, M., Iurlo, A., Orofino, N., Sica, S., Sorà, F., Lunghi, F., Ciceri, F., et al. (2020) · Blood · doi:10.1182/blood.2019002969 · Cited by 100
The Japan Adult Leukemia Study Group, Takahashi, N., Tauchi, T., Kitamura, K., Miyamura, K., Saburi, Y., Hatta, Y., Miyata, Y., Kobayashi, S., Usuki, K., et al. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2334-x · Cited by 99
A common phosphotyrosine signature for the Bcr-Abl kinase
Goss, V. L., Lee, K. A., Moritz, A., Nardone, J., Spek, E. J., MacNeill, J., Rush, A. J., Comb, M. J., & Polakiewicz, R. D. (2006) · Blood · doi:10.1182/blood-2005-08-3399 · Cited by 96
Zhou, H., Mak, P. Y., Mu, H., Mak, D. H. F., Zeng, Z., Cortes, J. E., Liu, Q., Andreeff, M., & Carter, B. Z. (2017) · Leukemia · doi:10.1038/leu.2017.87 · Cited by 93
Josephs, D. H., Fisher, D. S., Spicer, J. F., & Flanagan, R. J. (2013) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318292b931 · Cited by 89
Khorashad, J. S., Milojković, D., Mehta, P., Anand, M., Ghorashian, S., Reid, A. G., Melo, V. D., Babb, A., de Lavallade, H., Olavarría, E., et al. (2007) · Blood · doi:10.1182/blood-2007-06-096396 · Cited by 87
Cheloni, G., Tanturli, M., Tusa, I., DeSouza, N. H., Shan, Y., Gozzini, A., Mazurier, F., Rovida, E., Li, S., & Sbarba, P. D. (2017) · Blood · doi:10.1182/blood-2016-10-745588 · Cited by 84
Ponatinib: A Review of Efficacy and Safety
Massaro, F., Molica, M., & Breccia, M. (2017) · Current Cancer Drug Targets · doi:10.2174/1568009617666171002142659 · Cited by 83
Dorsey, J. F., Cunnick, J. M., Mane, S., & Wu, J. (2002) · Blood · doi:10.1182/blood.v99.4.1388 · Cited by 79
Zhou, L. L., Zhao, Y. S., Ringrose, A., DeGeer, D., Kennah, E., Lin, A. E.-J., Sheng, G., Li, X., Turhan, A. G., & Jiang, X. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072316 · Cited by 74
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells
Weisberg, E., Wright, R. D., McMillin, D. W., Mitsiades, C. S., Ray, A., Barrett, R., Adamia, S., Stone, R. M., Galinsky, I. A., Kung, A. L., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2331 · Cited by 74
Airiau, K., Mahon, F., Josselin, M., Jeanneteau, M., & Belloc, F. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.309 · Cited by 73
Cortes, J. E., Apperley, J. F., DeAngelo, D. J., Deininger, M. W., Kota, V. K., Rousselot, P. H., & Gambacorti-Passerini, C. B. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0685-2 · Cited by 73
Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival
Chen, Y., Peng, C., Abraham, S. A., Shan, Y., Guo, Z., DeSouza, N. H., Cheloni, G., Li, D., Holyoake, T. L., & Li, S. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66129 · Cited by 65
Acute dasatinib exposure commits Bcr-Abl–dependent cells to apoptosis
Snead, J. L., O’Hare, T., Adrian, L. T., Eide, C. A., Lange, T., Druker, B. J., & Deininger, M. W. (2009) · Blood · doi:10.1182/blood-2007-10-113969 · Cited by 60
Self-citationDasatinib treatment for Philadelphia chromosome‐positive leukemias
Khoury, H. J., Guilhot, F., Hughes, T. P., Kim, D., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24155 · Cited by 53
Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations
Traer, E. A., Javidi‐Sharifi, N., Agarwal, A., Dunlap, J. B., English, I. A., Martinez, J., Tyner, J. W., Wong, M., & Druker, B. J. (2014) · Blood · doi:10.1182/blood-2013-07-518381 · Cited by 52
Self-citationWillemsen‐Seegers, N., Uitdehaag, J. C. M., Prinsen, M. B. W., de Vetter, J. R. F., de Man, J., Sawa, M., Kawase, Y., Buijsman, R. C., & Zaman, G. J. R. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.12.019 · Cited by 49
Lai, D., Chen, M., Su, J., Liu, X., Rothe, K., Hu, K., Forrest, D. L., Eaves, C. J., Morin, G. B., & Jiang, X. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8735 · Cited by 47
Giotopoulos, G., van der Weyden, L., Osaki, H., Rust, A. G., Gallipoli, P., Meduri, E., Horton, S. J., Chan, W.-I., Foster, D., Prinjha, R. K., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20141661 · Cited by 44
Kim, T., Tyndel, M. S., Zhang, Z., Ahn, J., Choi, S.-H., Szardenings, M., Lipton, J. H., Kim, H., & Hwan, D. K. D. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.06.009 · Cited by 40
Schmitt, M. W., Pritchard, J. R., Leighow, S. M., Aminov, B. I., Beppu, L. W., Kim, D. S., Hodgson, J., Rivera, V. M., Loeb, L. A., & Radich, J. P. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0167 · Cited by 39
Gunnarsson, N., Sandin, F., Höglund, M., Stenke, L., Björkholm, M., Lambe, M. P., Olsson‐Strömberg, U., Richter, J., & Själander, A. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12743 · Cited by 38
BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl
Hemmeryckx, B., Reichert, A., Watanabe, M., Kaartinen, V., de Jong, R., Pattengale, P. K., Groffen, J., & Heisterkamp, N. (2002) · Oncogene · doi:10.1038/sj.onc.1205452 · Cited by 29
O’Hare, T., Eide, C. A., Agarwal, A., Adrian, L. T., Zabriskie, M. S., MacKenzie, R. J., LaTocha, D. H., Johnson, K. J., You, H., Luo, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3904 · Cited by 27
Self-citationA High-Throughput Method for Measuring Drug Residence Time Using the Transcreener ADP Assay
Kumar, M. A., & Lowery, R. G. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217695080 · Cited by 26
Monitoring of leukemia stem cells in chronic myeloid leukemia patients
Cui, J., Zhu, Z., Liu, S., Li, Q., Li, M., Cheng, H. W., Zhong, Z., Li, W., You, Y., Zhu, X., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1421755 · Cited by 12
Cited by
Protein degraders enter the clinic — a new approach to cancer therapy
Chirnomas, D., Hornberger, K. R., & Crews, C. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00736-3 · Cited by 658
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Complex roles of cAMP–PKA–CREB signaling in cancer
Zhang, H., Kong, Q., Wang, J., Jiang, Y., & Hua, H. (2020) · Experimental Hematology & Oncology · doi:10.1186/s40164-020-00191-1 · Cited by 466
Cell-cell communication: New insights and clinical implications
Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., & Mao, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01888-z · Cited by 433
Principles and therapeutic applications of adaptive immunity
Chi, H., Pepper, M., & Thomas, P. G. (2024) · Cell · doi:10.1016/j.cell.2024.03.037 · Cited by 330
Metadata
- Authors
- Braun, T. P., Eide, C. A., & Druker, B. J.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 37
- Issue
- 4
- Pages
- 530-542
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W3015686339
- Cited by
- 483
- References
- 143
- FWCI
- 35.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.